Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

The second dose of Oxford-AstraZeneca COVID-19 vaccine will be administered from Wednesday (April 28), says State Minister of Production, Supply, and Regulation of Pharmaceuticals Prof. Channa ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

AstraZeneca's lengthy and turbulent development ... The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb's ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

The second scenario consisted of cases in which people received a booster dose of CoronaVac as well ... there are also the viral vector vaccines (AstraZeneca and Janssen), in which another ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is ...

The judge also dissolved his temporary restraining order on the policy. As President Donald Trump's second administration continued its effort to swiftly reshape the federal government ...